MARKET

PCVX

PCVX

Vaxcyte, Inc.
NASDAQ
55.50
+0.84
+1.54%
Pre Market: 56.36 +0.86 +1.55% 08:22 07/28 EDT
OPEN
54.77
PREV CLOSE
54.66
HIGH
56.36
LOW
54.12
VOLUME
21
TURNOVER
0
52 WEEK HIGH
65.00
52 WEEK LOW
29.08
MARKET CAP
8.01B
P/E (TTM)
-8.0525
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PCVX last week (0720-0724)?
Weekly Report · 1d ago
Catalyst Watch: Tech majors report, FOMC, Jersey Mike's IPO and more oil anxiety
Seeking Alpha · 3d ago
Vaxcyte: Clinical-Stage Vaccine Disrupter With Vast Near-Term Potential
Seeking Alpha · 5d ago
Weekly Report: what happened at PCVX last week (0713-0717)?
Weekly Report · 07/20 09:17
Vaxcyte files Form 3 initial beneficial ownership statement for director John Markels
PUBT · 07/16 20:56
Vaxcyte names John Markels to board as Heath Lukatch retires
PUBT · 07/15 20:07
Guggenheim Reaffirms Their Buy Rating on Vaxcyte (PCVX)
TipRanks · 07/14 11:16
Weekly Report: what happened at PCVX last week (0706-0710)?
Weekly Report · 07/13 09:17
More
About PCVX
Vaxcyte, Inc. is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company's pipeline includes VAX-31, VAX-24 and VAX-XL. VAX-31, a 31-valent PCV candidate being evaluated in the OPUS Phase III adult clinical program and in a Phase II infant clinical program, is being developed for the prevention of IPD and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-XL leverages the Company’s carrier-sparing, site-specific conjugation technology. It is re-engineering the way highly complex vaccines are made through XpressCF, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella.

Webull offers Vaxcyte Inc stock information, including NASDAQ: PCVX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCVX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PCVX stock methods without spending real money on the virtual paper trading platform.